PRA Health Sciences ROE 2013-2018 | PRAH

Current and historical return on equity (ROE) values for PRA Health Sciences (PRAH) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. PRA Health Sciences ROE for the three months ending September 30, 2018 was 25.75%.
PRA Health Sciences ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $0.07B $0.98B 6.92%
2018-06-30 $0.11B $0.95B 11.99%
2018-03-31 $0.10B $0.95B 11.02%
2017-12-31 $0.09B $0.94B 9.96%
2017-09-30 $0.12B $0.94B 14.23%
2017-06-30 $0.10B $0.85B 12.94%
2017-03-31 $0.11B $0.78B 14.75%
2016-12-31 $0.07B $0.73B 9.41%
2016-09-30 $0.08B $0.74B 11.59%
2016-06-30 $0.08B $0.71B 10.78%
2016-03-31 $0.05B $0.71B 7.00%
2015-12-31 $0.08B $0.70B 11.97%
2015-09-30 $0.03B $0.69B 4.42%
2015-06-30 $0.01B $0.70B 1.15%
2015-03-31 $-0.01B $0.65B -1.63%
2014-12-31 $-0.04B $0.68B -9.25%
2014-09-30 $-0.01B $0.42B -5.92%
2014-06-30 $-0.10B $0.46B -83.98%
2014-03-31 $-0.09B $0.00B inf%
2013-12-31 $-0.08B $0.00B -177.27%
Sector Industry Market Cap Revenue
Medical Medical Services $6.277B $2.259B
PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina.
Stock Name Country Market Cap PE Ratio
Express Scripts Holding (ESRX) United States $54.638B 11.29
ICON (ICLR) Ireland $6.920B 21.69
Charles River Laboratories (CRL) United States $6.012B 21.08
Premier (PINC) United States $5.275B 17.90
INC Research Holdings (SYNH) United States $4.800B 19.38
HealthEquity (HQY) United States $4.740B 99.21
Teladoc (TDOC) United States $3.711B 0.00
AMN Healthcare Services Inc (AMN) United States $2.883B 19.78
NovoCure (NVCR) Jersey $2.674B 0.00
BioTelemetry (BEAT) United States $2.016B 35.61
Medpace Holdings (MEDP) United States $1.851B 22.91
Healthways (TVTY) United States $1.480B 18.20
Intrexon (XON) United States $1.304B 0.00
IKang Healthcare (KANG) China $1.169B 58.03
CareDx (CDNA) United States $1.020B 0.00
Natera (NTRA) United States $0.957B 0.00
China Cord Blood (CO) China $0.802B 21.29
Apollo Medical Holdings (AMEH) United States $0.635B 0.00
Surgery Partners (SGRY) United States $0.618B 0.00
Establishment Labs Holdings (ESTA) $0.521B 0.00
Civitas Solutions (CIVI) United States $0.516B 10.18
OncoCyte (OCX) United States $0.069B 0.00
Interpace Diagnostics (IDXG) United States $0.032B 0.00
Cancer Genetics (CGIX) United States $0.013B 0.00
OpGen (OPGN) United States $0.007B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.004B 0.00